LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Long Pond Capital, LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Long Pond Capital, LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Oct 29(Reuters) - Adidas's North America sales recorded the weakest growth among the German sportswear maker's regions in the third quarter, the company reported on Wednesday. Revenues for its Adidas brand in North America rose 8% on the year, excluding the impact of currency movements, lagging other markets, which grew between 10% and 21% in the quarter. Adidas's brand growth...

Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026 BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023   INCHEON, Korea--(BUSINESS WIRE)-- Samsung Bioepis...